Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

A new treatment, which is set to transform the lives of type two diabetes patients, is now on the PBS - halving its price.

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

Endocrinologic and Metabolic Drugs Advisory Committee, the majority of panel members voted against the approval of sotagliflozin (Zynquista™) for use as an adjunct to insulin therapy for glycemic ...

Osteoarthritis, the most common form of arthritis, is primarily caused by wear and tear on the protective layer of cartilage ...

Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...

Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic ... off the shortage list, Lilly and Novo aim to curtail the market of online pharmacies such as ...